Jazz Pharmaceuticals is pressing pause on a phase 1 sleep disorder med due to adverse events despite one executive saying that it “achieved proof of concept.” The comments were relayed by Chief ...
Axsome Therapeutics, Inc. AXSM announced that it has entered into a definitive agreement with Jazz Pharmaceuticals JAZZ to acquire the latter’s new sleep drug, Sunosi (solriamfetol). The drug is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback